How to Help Your Patients Save Money on Yupelri: A Provider's Guide to Savings Programs

Yupelri (revefenacin) is a clinically valuable medication for COPD patients who need or prefer nebulized bronchodilator therapy. But with a list price of $1,655.34 per 30-day supply and no generic alternative, cost can be a significant barrier to initiation and adherence. Providers who understand the available savings landscape can meaningfully reduce out-of-pocket burden for their patients and keep them on therapy. Here's a comprehensive 2026 guide.

Understanding Yupelri's Cost Structure

The cost landscape for Yupelri varies significantly by payer type:

WAC (list price): $1,655.34 per 30-day supply (per Viatris, 2024)

Commercial insurance: Covered by ~73% of plans; ~90% of commercially insured patients pay $0 out of pocket (per Viatris data)

Medicare Part B: Covers 80% as DME nebulizer solution; patient pays 20% (~$330/month without supplemental coverage)

Medicare + Medigap: Supplemental insurance covers the 20% coinsurance — patient may pay $0

Uninsured: Cash price $1,439–$1,826/month; patient assistance program available

Program 1: The Yupelri Savings Card (Commercially Insured Patients)

The most important tool for commercially insured patients is the Yupelri Savings Card from Viatris. As the prescriber, your awareness and promotion of this program can significantly improve adherence.

Key details:

Eligible commercially insured patients may pay as little as $0 per monthly fill

Valid for up to 12 fills per calendar year (12 months of coverage)

Enrollment: activatethecard.com/yupelri or yupelri.com/copay

Patient hotline: 866-255-9018 (Mon–Fri 8 AM–8 PM EST)

Exclusions: NOT valid for Medicare, Medicaid, TRICARE, VA, or other federal/state program beneficiaries. Not for uninsured patients. Massachusetts residents may face additional restrictions per state law.

Clinical practice tip: Add a step in your Yupelri prescribing workflow to ask "Is this patient commercially insured?" If yes, provide information about the savings card or have your medical assistant print the enrollment page at checkout.

Program 2: Viatris Patient Assistance Program (Uninsured/Underinsured)

For patients without adequate insurance coverage and who do not qualify for the savings card, the Viatris Patient Assistance Program (PAP) — Group One Medicines — provides Yupelri at no cost to eligible patients:

Phone: 800-796-9526

Email: ViatrisPAP@viatris.com

Application fax: 877-427-7290

Program duration: 12 months, maximum 11 refills per enrollment period

Provider participation is required for PAP enrollment. Have your office staff identify uninsured or underinsured patients at the time of prescribing and initiate the application process proactively — don't wait for the patient to ask.

Program 3: Medicare Part B Coverage Optimization

For Medicare patients, ensuring correct billing under Part B (rather than Part D) is critical for maximizing coverage:

HCPCS J-code: J7677 (revefenacin inhalation solution, 1 mcg, DME-administered)

Coverage: Medicare Part B covers 80% of the allowed amount; patient pays 20% coinsurance

Medigap supplemental: Covers the patient's 20% share — patients with both Medicare and Medigap may pay $0

Medicare Advantage (Part C): Most Medicare Advantage plans also cover Yupelri; formulary varies by plan — verify before prescribing

Nebulizer DME coverage: Medicare Part B also covers the nebulizer machine as DME when medical necessity is documented in the record

Important: The manufacturer savings card is NOT valid for Medicare beneficiaries regardless of whether Medicare is paying the full cost. Advise patients with Medicare accordingly.

Maximizing Prior Authorization Success

Prior authorization requirements are the most common source of access delays for Yupelri. Optimizing your PA workflow reduces the time patients wait for coverage approval:

Submit the PA at the time of prescribing, not after the pharmacy triggers a rejection.

Document clearly: COPD severity (moderate-to-severe, documented FEV1/FVC and % predicted), plus one of: tiotropium failure/contraindication OR physical/cognitive inability to use handheld inhalers.

Track expiration dates: PA approvals expire (typically annually). Proactive reauthorization prevents therapy interruptions.

If denied, request peer-to-peer review. Detailed clinical cases with specific documented limitations have high success rates at the peer-to-peer level.

Directing Patients to Specialty Pharmacies and Mail-Order

In addition to savings programs, where patients fill their prescription affects their access experience. Retail pharmacy stocking of Yupelri is inconsistent — most community pharmacies don't carry it regularly. Direct your office to:

Route all Yupelri prescriptions to a preferred specialty pharmacy

Recommend mail-order for patients on long-term Yupelri therapy (90-day supplies via Express Scripts, CVS Caremark, Optum Rx)

Tell patients about medfinder.com for real-time pharmacy stock checking when they encounter retail pharmacy access issues

Provider Savings Checklist for Yupelri Prescriptions

Identify insurance type at prescribing (commercial vs Medicare vs uninsured)

For commercial: Inform patient about Savings Card (activatethecard.com/yupelri)

For Medicare: Ensure J7677 billing under Part B; assess Medigap coverage

For uninsured: Initiate Viatris PAP application (800-796-9526)

Submit prior authorization at time of prescribing with complete clinical documentation

Route prescription to specialty pharmacy or mail-order

Advise patients about medfinder.com for locating retail stock when needed

For the complete provider access guide including pharmacy routing and PA workflow details, see: How to Help Your Patients Find Yupelri in Stock: A Provider's Guide. For provider tools and resources, visit medfinder.com/providers.